Archiv
Archiv anzeigen:
bis


Brigatinib for ALK-Positive, Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Camidge DR et al. N Engl J Med 2018 Sep 25

Progression-free survival was prolonged with front-line brigatinib versus crizotinib.


Front-Line Therapy for Extensive-Stage, Small Cell Lung Cancer: A New Standard

Anne S. Tsao, MD reviewing Horn L et al. N Engl J Med 2018 Sep 25

Adding atezolizumab to chemotherapy significantly improved overall and progression-free survival.


A New Standard of Care for Squamous Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Paz-Ares L et al. N Engl J Med 2018 Sep 25

Adding the PD-1 inhibitor pembrolizumab to carboplatin-taxane chemotherapy significantly improved response and survival.


Durvalumab After Chemoradiation for Advanced Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Antonia SJ et al. N Engl J Med 2018 Sep 25

Two-year overall survival was significantly improved with durvalumab versus placebo.


Compression Therapy to Prevent Post-Thrombotic Syndrome

David Green, MD, PhD reviewing Amin EE et al. Blood 2018 Sep 20

Compression after deep venous thrombosis reduced residual vein obstruction; absence of residual vein obstruction was associated with lower prevalence of post-thrombotic syndrome.


Liver Disease Associated with Androgen Deprivation Therapy

Robert Dreicer, MD, MS, MACP, FASCO reviewing Gild P et al. J Urol 2018 Sep

Prostate cancer patients receiving ADT were significantly more likely to develop liver disease than those not receiving ADT.


Omission of Axillary Dissection for Minimal Node-Positive Breast Cancer

William J. Gradishar, MD reviewing Galimberti V et al. Lancet Oncol 2018 Sep 5

Long-term follow-up data confirm that axillary dissection is unnecessary in patients with minimal tumor burden in the sentinel nodes.


Ruxolitinib and Azacitidine for Myelofibrosis

David Green, MD, PhD reviewing Masarova L et al. Blood 2018 Sep 5

The combination decreased symptoms, spleen size, and marrow fibrosis in more than half of patients, but at a cost of frequent and serious cytopenias.


Updated Guidelines for Treatment of Advanced HER2-Positive Breast Cancer

William J. Gradishar, MD reviewing Giordano SH et al. J Clin Oncol 2018 Sep 10

Recommendations have not fundamentally changed since the last update in 2014.


Resistance to Enzalutamide for Metastatic Castration-Resistant Prostate Cancer

Robert Dreicer, MD, MS, MACP, FASCO reviewing Attard G et al. Am J Clin Oncol 2018 Sep 1

The use of abiraterone and prednisone failed to improve progression-free survival.


Archiv
Seite von 74
Editorial Member Board Empfehlungen

Prof. Dr. med. Beat Thürlimann

Brustzentrum St. Gallen
Kantonsspital St. Gallen

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

Im «New England Journal of Medicine» sind wieder einige interessante, auch «practice changing» Publikationen erschienen.

Kommentar weiterlesen

Enzalutamide for Castration-Resistant PSA-Only Prostate Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Hussain M et al. N Engl J Med 2018 Jun 28, Smith MR. N Engl J Med 2018 Jun 28

Metastasis-free survival was significantly improved with enzalutamide versus placebo.


First-Line Atezolizumab for Metastatic Nonsquamous NSCLC

Anne S. Tsao, MD reviewing Socinski MA et al. N Engl J Med 2018 Jun 14

Adding atezolizumab to bevacizumab and chemotherapy improved survival in chemotherapy-naive patients with non–small-cell lung cancer, regardless of EGFR or ALK mutation status.


Cytoreductive Nephrectomy for Metastatic Kidney Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Méjean A et al. N Engl J Med 2018 Jun 3, Motzer RJ and Russo P. N Engl J Med 2018 Jun 3

Adding nephrectomy to standard sunitinib therapy did not improve survival in patients with poor- and intermediate-risk disease.


ASCO 2018 Report — Breast Cancer

William J. Gradishar, MD

Highlights of the latest treatments


Intensive Surveillance for Colorectal Cancer

David H. Ilson, MD, PhD reviewing Wille-Jørgensen P et al. JAMA 2018 May 22, Sanoff HK. JAMA 2018 May 22

More- versus less-frequent testing did not improve survival after curative treatment for patients with stage II–III disease.


Fewer Patients with Breast Cancer Require Chemotherapy

William J. Gradishar, MD reviewing Sparano JA et al. N Engl J Med 2018 Jun 3

Outcomes were noninferior with endocrine therapy alone versus chemo-endocrine therapy in patients with intermediate recurrence scores.


Chemotherapy for Isolated Locoregional Recurrence of Breast Cancer

Henry Mark Kuerer, MD, PhD, FACS reviewing Wapnir IL et al. J Clin Oncol 2018 Apr 10

Long-term results confirm a benefit for ER-negative but not ER-positive patients.


Neoadjuvant Nivolumab for Resectable Lung Cancer

Anne S. Tsao, MD reviewing Forde PM et al. N Engl J Med 2018 Apr 16

A major pathological response was seen in 45% of patients.


First-Line Nivolumab plus Ipilimumab for Advanced Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Hellmann MD et al. N Engl J Med 2018 Apr 16

Progression-free survival was improved versus chemotherapy for patients with high tumor mutation burden.


First-Line Lenvatinib vs. Sorafenib for Unresectable Hepatocellular Carcinoma

David H. Ilson, MD, PhD reviewing Kudo M et al. Lancet 2018 Feb 9, Reig M and Bruix J. Lancet 2018 Feb 9

Overall survival was noninferior and progression-free survival and response were superior with lenvatinib.